Insider trade

Engene Therapeutics (ENGN)10% owner bought ~$87K

Forbion Growth Opportunities Fund I Cooperatief U.A., 10% owner at Engene Therapeutics, bought ~$87K of Engene Therapeutics shares.

~$87K
Approx. value · 9,620 sh @ $9.09: 2.02M
Holds after · shares reported

Traded: Dec 29, 2023
Filed: Oct 18, 2024

View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Engene Therapeutics

For Engene Therapeutics, OQRO holds 1 insider filing (SEC Form 4 or Form 144) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its ENGN page.

Other recent filings by Forbion Growth Opportunities Fund I Cooperatief U.A., 10% owner

The full history of Forbion Growth Opportunities Fund I Cooperatief U.A., 10% owner is on the profile page.

How this filing works

Other disclosures at Engene Therapeutics

Everything OQRO holds on this company is on its ENGN page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

Unlock OQRO Pro Already have an account? Log in

OQRO Pro is a paid subscription. You see the price before you pay

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data